Case 1:24-cv-24617-CMA
THE HAITIAN DIASPORA POLITICAL
ACTION COMMITTEE (HDPAC) et al
vs
THE AMERICAN RED CROSS et al
https://bloximages.newyork1.vip.townnews.com/miamitimesonline.com/content/tncms/assets/v3/editorial/d/47/d47eae54-ace3-11ef-87e2-7b053e4d12ae/67475516181dd.pdf.pdf
US Tax Dollars Funded Every New Pharmaceutical in the Last Decade
The scope of the public sector’s contribution to drug discovery and development identified in is study is somewhat overwhelming. Our analysis focused on identifying HIN funded research associated with the 356 drugs that were approved from 2010-2019 or their 219 distinct biological targets. We also examined the timelines of clinical development, proxy measures of their innovativeness or importance, and the patents resulting from the NIH-funded research. We identified 2.2 million published research papers related to these drugs or targets, of which 21% acknowledged funding from the NIH totaling 332 thousand fiscal years of research funding amassing more than $230 billion. This research was also cited in 22 thousand issued US patents.
While the stated mission of the NIH is “to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability,” our analysis identified relatively little direct investment in drug development. We identified 244 thousand publications directly related to these drugs, of which 16% acknowledged NIH funding totaling $36 billion. In contrast, we identified 2 million publications related to the biological targets for these drugs, of which 21% acknowledged NIH funding totaling $195 billion. Two thirds of the research funding we identified was for investigator-initiated Research Projects or Research Program Projects and Centers that provide research infrastructure, and less than one third was related to government-initiated and managed Cooperative Agreements of Intramural Research.
This pattern of funding is consistent with the linear model of innovation that underlies federal science policy. In this model, there is a flow of fundamental knowledge from publicly funded, basic science, sometimes referred to as “scientific capital,” to private industry, which provides the economic capital investments and technical capabilities required for drug development, manufacture, and marketing. In our study, we found that every one of the new drugs approved from 2010-2019 was developed and distributed by companies, which are estimated to invest as much as $1.5 billion on average in each new product launched.
There are, however, other goals inherent in federal funding, which are not stated in the NIH mission statement, but rather the Bayh-Dole Act, which governs the transfer of which NIH-funded research from non-profit institutions that receive NIH funding to industry. The stated objectives of the Bayh-Dole Act (35 U.S.C. §200 – 212) include “to promote the utilization of inventions arising from federally supported research or development; ….. ; to ensure that inventions made by nonprofit organizations and small business firms are used in a manner to promote free competition and enterprise; to promote the commercialization and public availability of inventions made in the United States by United States industry and labor; to ensure that the Government obtains sufficient rights in federally supported inventions to meet the needs of the Government and protect the public against nonuse or unreasonable use of Inventions…”.
Moar
https://www.ineteconomics.org/perspectives/blog/us-tax-dollars-funded-every-new-pharmaceutical-in-the-last-decade